




## EXCLUSIVE: John Boehner Helps Americans Make A Fortune From Marijuana

Promoted Content

[Login](#)[Register](#)

## Spotlight - Sponsored

Sponsored Content

 [Spotlight - Sponsored \(/news/list/spotlight-companies\)](/news/list/spotlight-companies)

- Biotechnology (/news/list/2-defensive/205-consumer-defensive/20635-biotechnology)

# Lexaria Bioscience Creates and Brands Subsidiary Companies

*Spotlight News (/user/SpotlightNews)*  Follow | Wednesday, 10 October 2018 08:00 (EST)

liary companies."%0D%0A%0D%0Ahttps://www.equities.com/news/lexaria-bioscience-creates-and-brands-subsidiary-companies)



### **Lexaria Bioscience Corp.** (LXRP[OTCQB])

(../companies/lxrp) - \$1.48 (../companies/lxrp) ▲

) (LXX:CNX[CNQ] (../companies/lxx-cnx) - \$1.95 ▲0.04 (2.09%)

(../companies/lxx-cnx) ▲ ) (,[] (../companies/) - \$0. (%)

(../companies/) ▲ ) a drug delivery platform

innovator, is pleased to announce it has completed the creation of four wholly-owned subsidiary companies.

This new corporate structure more suitably reflects the distinct customer bases and business applications for each subsidiary, thereby allowing the Company to focus its future research and consider financing structures and industry partnerships specifically optimized to each.

Each of the companies has a new website currently under construction that is individualized for corporate purposes specific to that company, but also clearly branded as part of the Lexaria group of companies. The subsidiaries are each empowered with Lexaria's patented DehydraTECH™ technology.

**Lexaria CanPharm Corp.,** a Canadian company focused on providing DehydraTECH technology and other enhancements to the global cannabis industry. Lexaria CanPharm Corp. administers the Company's current cannabis-related patent portfolio, which is one of the largest cannabis-focused intellectual property suites in the world. Lexaria CanPharm is in active discussions related to licensing its technology to companies located in Canada, the USA, and Europe.



**Lexaria Nicotine Corp.,** a US company with a global license to provide DehydraTECH technology to the global nicotine and tobacco industries. Lexaria Nicotine Corp. administers the Company's nicotine-related patent portfolio. Since mid 2017 the Company has had discussions with several leading nicotine/tobacco companies around the world and will continue to work towards a healthier consumer nicotine sector with potential industry partners well-established in the industry. Lexaria Nicotine Corp. is focused on reduced-risk nicotine solutions to help hundreds of million of existing smokers lead healthier lives with lessened risk of cancer through avoidance of combustible products.



**Lexaria Hemp Corp.,** a US company globally licensed to provide DehydraTECH to the rapidly growing hemp-based foods and supplements industries. Lexaria Hemp Corp. is currently involved in discussions with a number of companies regarding the utilization of its technology in CBD-from-hemp products for the Canadian and US markets following recent



announcements of regulatory advancement in both countries. Discussions with companies in other global markets are also underway with reportable progress expected soon.

Lexaria Hemp Corp. will also soon announce the creation of a new wholly-owned brand that will be introducing a new category-killer product at the upcoming MJBiz conference in Las Vegas on November 14-16, 2018 where Lexaria will be exhibiting at booth 3227. Lexaria will set new standards that exceed consumers expectations and continue to advance the industry as we have done so since 2014.

**Lexaria Pharmaceutical Corp.**, a US company globally empowered to license DehydraTECH to the large and diverse pharmaceutical sectors, including pain relief, vitamins, PDE5 inhibitors, hormone treatments, central nervous system conditions, and more. Lexaria Pharma will manage the broadest set of intellectual property of all the Lexaria family of companies and is in the R&D and product development phase.



Lexaria also announces it will utilize wholly-owned Poviva Tea Corp., to advance the existing ViPova Tea and Coffee consumer brands. Recent signs of legislative easing in the US support the possibility of renewed distribution possibilities for these brands.

Separately, Lexaria has received US\$33,000 from the exercise of 330,000 options at the price of US\$0.10 previously granted to a third party who is neither an officer nor director of the Company. No commissions or placement fees have been paid related to the funds received from these options exercised. Proceeds will be used for general corporate purposes.

### **About Lexaria**



Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has eight patents granted in the USA and in Australia and has filed over 50 patent applications worldwide across ten patent families. Lexaria's technology provides increases in intestinal absorption rates; more

rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

*In the interest of full disclosure, we call the reader's attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.*

**DISCLOSURE:** *The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com (<http://www.equities.com>). Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: <http://www.equities.com/disclaimer> (<http://www.equities.com/disclaimer>)*

## Companies

	Symbol	Name	Price	Change	%	Volume
 Follow	LXRP (/companies/lxrp)	Lexaria Bioscience Corp. (/companies/lxrp)	1.48	0.03	2.07	316,604
 Follow	LXX:CNX (/companies/lxx-cnx)	Lexaria Bioscience Corp (/companies/lxx-cnx)	1.95	0.04	2.09	112,839